Indian Journal of Physical Medicine and Rehabilitation

Register      Login

VOLUME 24 , ISSUE 4 ( December, 2013 ) > List of Articles


Efficacy of Diacerein in the Treatment of Osteo-arthritis of Knee

U Singh, Loitongbam L Sushil Singh, Handa Gita, S L Yadav

Citation Information : Singh U, Singh LL, Gita H, Yadav SL. Efficacy of Diacerein in the Treatment of Osteo-arthritis of Knee. Indian J Phy Med Rehab 2013; 24 (4):92-98.

DOI: 10.5005/ijopmr-24-4-92

Published Online: 01-12-2013

Copyright Statement:  Copyright © 2013; The Author(s).


Osteo-arthritis, the most common joint disease of human being, presents with pain and stiffness of the affected joints, feeling of instabilities, deformities and severe loss of function of the involved joint affecting activities of daily livings as well as economic burden.

The present study evaluates the efficacy and adverse effects of diacerein, an anti-inflammatory drug now being considered as a disease modifying drug in osteo-arthritis on 38 patients. After 6 weeks of intervention, diacerein showed statistically significant superiority versus aceclofenac as assessed with WOMAC A (P<0.0001), WOMAC B (P< 0.0001), WOMAC C (P<0.0001) and secondary efficacy variable like NSAIDs (aceclofenac) intake from the baseline and at the efficacy time point at 6 weeks and 12 weeks(P<0.0001), demonstrating the better efficacy of diacerein over aceclofenac. This superiority was already evident from 6th week for all the parameters. It was more significant after completion of the study.

PDF Share
  1. Synovial inflammation in patients with early osteoarthritis of the knee. Rheumatology 1990;17:1662-9.
  2. The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee. Arthritis Rheum 2007;56:4055-64.
  3. The natural course of untreated osteoarthritis of the knee. Clin Orthop 1977;123:130-1.
  4. Harrison's principles of internal medicine. 14th ed. New York: MacGraw-Hill, 1989:1935-41.
  5. The effect of the synovial tissue on the breakdown of articular cartilage in organ culture. Osteoarthritis Cartilage 1977;20:1359-71.
  6. Serum and synovial fluid levels of serum amyloid A protein and C-reactive protein in inflammatory and non-inflammatory arthritis. J Rheumatol 1988;15:942-5.
  7. Low level increase in serum, C-reactive protein are present in the early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 1997;40:723-7.
  8. Diacerein as a diseasemodulating agent in osteo-arthritis. Curr Rheumatol Rep 2001;3:479-83.
  9. Inhibition of IL-1 B-induced activation of MEK/ ERK pathway and DNA binding of N F kappa B and AP-1: potential mechanism of diacerein in osteoarthritis. Biorheology 2006; 43: 577-87.
  10. Clinical pharmacokinetics of diacerein. Clin Pharmacokinet 1998;35:347-59.
  11. Pharmacokinetics of diacerein in patients with liver cirrhosis. Biopharm Drug Dispos 1993;14:401-8.
  12. A meta-analysis of controlled clinical studies with diacerein in the treatment of osteo-arthritis. Arch Intern Med 2006;166:1899-906.
  13. Efficacy and safety of diacerein in osteoarthritis of the knee: a randomized, multicenter, double-dummy, diclofenac-controlled trial in China. APLAR J Rheumatol 2006;9:64-9.
  14. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum 2000;43:2339-48.
  15. Efficacy and safety of diacerein in early knee osteo-arthritis. Clin Rheumatol 2009;15.
  16. Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy. J Rheumatol 1988;15:1833-40.
  17. The WOMAC knee and hip osteoarthritis Indices: Development, validation, globalization and influence on the development of the AUSCAN Hand Osteoarthritis Indices. Clin Exp Rheumatol 2005;23:148-53.
  18. In Melzack R, editor. Pain Measurement and Assessment. New York: Raven Press 1983;33-40.
  19. Efficacy of diacerein on the symptoms and radiographic progression of osteoarthritis. Medicine 2002;31:4S13-5.
  20. Cox-2 inhibitors: cardiovascular safety. JK Sci 2005;7:61-2.
  21. Chondroprotective drugs in degenerative joint diseases. Rheumatology (Oxford) 2006;45:129-38.
  22. Pharmacological therapy of osteoarthritis. Best Pract Res Clin Rheumatol 2001;15:583-93.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.